Sauchinone, a lignan from Saururus chinensis, attenuates neutrophil pro-inflammatory activity and acute lung injury.
Previous studies have shown that sauchinone modulates the expression of inflammatory mediators through mitogen-activated protein kinase (MAPK) pathways in various cell types. However, little information exists about the effect of sauchinone on neutrophils, which play a crucial role in inflammatory process such as acute lung injury (ALI). We found that sauchinone decreased the phosphorylation of p38 MAPK in lipopolysaccharide (LPS)-stimulated murine bone marrow neutrophils, but not ERK1/2 and JNK. Exposure of LPS-stimulated neutrophils to sauchinone or SB203580, a p38 inhibitor, diminished production of tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 compared to neutrophils cultured with LPS. Treatment with sauchinone decreased the level of phosphorylated ribosomal protein S6 (rpS6) in LPS-stimulated neutrophils. Systemic administration of sauchinone to mice led to reduced levels of phosphorylation of p38 and rpS6 in mice lungs given LPS, decreased TNF-α and MIP-2 production in bronchoalveolar lavage fluid, and also diminished the severity of LPS-induced lung injury, as determined by reduced neutrophil accumulation in the lungs, wet/dry weight ratio, and histological analysis. These results suggest that sauchinone diminishes LPS-induced neutrophil activation and ALI.
Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
Hui-Jing
HJ
Han
Mei
M
Li
Jong-Keun
JK
Son
Chang-Seob
CS
Seo
Seung-Won
SW
Song
Sang-Hyun
SH
Kwak
Hong-Beom
HB
Bae
D055371:Acute Lung Injury / Q000188:drug therapy* / Q000276:immunology; D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage* / Q000627:therapeutic use; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D054426:Chemokine CXCL2 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D004149:Dioxoles / Q000008:administration & dosage* / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000378:metabolism*; D017705:Lignans / Q000008:administration & dosage*; D008070:Lipopolysaccharides / Q000276:immunology; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D010766:Phosphorylation; D038601:Ribosomal Protein S6 / Q000378:metabolism; D032134:Saururaceae / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D001578:Benzopyrans; D054426:Chemokine CXCL2; D016207:Cytokines; D004149:Dioxoles; D018836:Inflammation Mediators; D017705:Lignans; D008070:Lipopolysaccharides; D038601:Ribosomal Protein S6; D014409:Tumor Necrosis Factor-alpha; C448579:ribosomal protein S6, mouse; C410958:sauchinone; D048051:p38 Mitogen-Activated Protein Kinases
Cytokines; LPS; Neutrophil; Sauchinone